Health Care • Medical/Dental Instruments
$412.62 ▼ -4.05
(-0.97%)
MKT CAP: $29.32B • VOL: 1.06M
52W L $224 52W H $438
WST // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $3.07B | $2.89B | $2.95B |
| YoY Revenue Growth % | +6.3% | -1.9% | — |
| Gross Profit | $1.10B | $998.5M | — |
| Gross Margin % | 35.9% | 34.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $584.9M | $569.9M | $676.0M |
| Operating Margin % | 19.0% | 19.7% | 22.9% |
| Net Income (GAAP) | $493.7M | $492.7M | $593.4M |
| EBITDA (Normalized) | $813.6M | $871.5M | $782.2M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $754.8M | $653.4M | $776.5M |
| Capital Expenditures (CapEx) | $285.9M | $377.0M | $132.7M |
| Free Cash Flow (FCF) | $468.9M | $276.4M | $643.8M |
| FCF Margin % | 15.3% | 9.6% | 21.8% |
| Return on Invested Capital (ROIC %) | 17.9% | 18.8% | 5.5% |
| Cash & Short-Term Equivalents | $791.3M | $484.6M | — |
| Total Debt (Short + Long Term) | $202.8M | $202.6M | $3.77B |
| Total Stockholders' Equity | $3.18B | $2.68B | $7.74B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR WST.